| metastatic-recurrent HNSCC (mHNSCC) | ||
| mHNSCC - L2 - all population | mHNSCC - L2 - PDL1 positive | |
| anti-PD-(L)1 | ||
| durvalumab based treatment | ||
| durvalumab alone | EAGLE ... | |
| nivolumab based treatment | ||
| nivolumab alone | CheckMate 141 | |
| pembrolizumab based treatment | ||
| pembrolizumab alone | KEYNOTE-040 ... | KEYNOTE-040 ... |
Study type:
delta: difference in rate or median (if available)
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-
